Stručni rad

https://doi.org/10.15836/ccar.2014.570

Contribution of Krka’s RAAS-acting Medicines in the Treatment of Hypertension: 25 Years of Clinical Experience.

Janez Kopač ; Krka, d. d., Novo mesto, Slovenija
Mateja Grošelj ; Krka, d. d., Novo mesto, Slovenija
Breda Barbič-Žagar orcid.org/0000-0002-1173-7361 ; Krka, d. d., Novo mesto, Slovenia

Sažetak

Krka has over 25 years of experience in the production of high-quality medicines acting on the renin-anigotensin-aldosterone system (RAAS) and has become one of the leading producers of them in Europe. Since its first introduction of a medicine acting on RAAS it has been performing international clinical studies in order to monitor the efficacy and safety of its products within the scope of the doctrine, enable doctors to gain their own experience with them, and prove their efficacy and safety in clinical practice. With the findings of the studies described in this article, we would like to present the contribution of Krka’s RAAS-acting medicines in the treatment of hypertension in over 25 years.

Ključne riječi

ACE inhibitors; angiotensin II receptor blockers; clinical studies; efficacy; safety

Hrčak ID:

139454

URI

https://hrcak.srce.hr/139454

Datum izdavanja:

20.1.2015.

Podaci na drugim jezicima: hrvatski

Posjeta: 1.718 *